93 related articles for article (PubMed ID: 36362028)
1. Anti-Metastatic Effect of Pyruvate Dehydrogenase Kinase 4 Inhibition in Bladder Cancer via the ERK, SRC, and JNK Pathways.
Lee EH; Chung JW; Sung E; Yoon BH; Jeon M; Park S; Chun SY; Lee JN; Kim BS; Kim HT; Kim TH; Choi SH; Yoo ES; Kwon TG; Kang HW; Kim WJ; Yun SJ; Lee S; Ha YS
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362028
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Pyruvate Dehydrogenase Kinase 4 Attenuates Myocardial and Mitochondrial Injury in Sepsis-Induced Cardiomyopathy.
Chen T; Ye L; Zhu J; Tan B; Yi Q; Sun Y; Xie Q; Xiang H; Wang R; Tian J; Xu H
J Infect Dis; 2024 Apr; 229(4):1178-1188. PubMed ID: 37624974
[TBL] [Abstract][Full Text] [Related]
3. Loss of the novel mitochondrial protein FAM210B promotes metastasis via PDK4-dependent metabolic reprogramming.
Sun S; Liu J; Zhao M; Han Y; Chen P; Mo Q; Wang B; Chen G; Fang Y; Tian Y; Zhou J; Ma D; Gao Q; Wu P
Cell Death Dis; 2017 Jun; 8(6):e2870. PubMed ID: 28594398
[TBL] [Abstract][Full Text] [Related]
4. Increased Expression of PDK4 Was Displayed in Gastric Cancer and Exhibited an Association With Glucose Metabolism.
Liu B; Zhang Y; Suo J
Front Genet; 2021; 12():689585. PubMed ID: 34220962
[TBL] [Abstract][Full Text] [Related]
5. PDK1: a new therapeutic target for glioblastoma?
Velpula KK; Tsung AJ
CNS Oncol; 2014 May; 3(3):177-9. PubMed ID: 25055123
[No Abstract] [Full Text] [Related]
6. 12-O-deacetyl-phomoxanthone A inhibits ovarian tumor growth and metastasis by downregulating PDK4.
Yang C; Xing S; Wei X; Lu J; Zhao G; Ma X; Dai Z; Liang X; Huang W; Liu Y; Jiang X; Zhu D
Biomed Pharmacother; 2024 May; 175():116736. PubMed ID: 38739992
[TBL] [Abstract][Full Text] [Related]
7. Author Correction: PDK4-dependent hypercatabolism and lactate production of senescent cells promotes cancer malignancy.
Dou X; Fu Q; Long Q; Liu S; Zou Y; Fu D; Xu Q; Jiang Z; Ren X; Zhang G; Wei X; Li Q; Campisi J; Zhao Y; Sun Y
Nat Metab; 2024 May; ():. PubMed ID: 38693321
[No Abstract] [Full Text] [Related]
8. Anti-oncogenic effects of dutasteride, a dual 5-alpha reductase inhibitor and a drug for benign prostate hyperplasia, in bladder cancer.
Seok J; Kwak HJ; Kwak Y; Lee M; Park KS; Kim A; Cho SG
J Transl Med; 2023 Feb; 21(1):129. PubMed ID: 36800968
[TBL] [Abstract][Full Text] [Related]
9. CEACAM1 Marks Highly Suppressive Intratumoral Regulatory T Cells for Targeted Depletion Therapy.
Jeon SH; Kang M; Jeon M; Chung Y; Kim AR; Lee YJ; Kim ES; Nam H; Park J; Lee JY; Shin EC; Seo SI; Park SH
Clin Cancer Res; 2023 May; 29(9):1794-1806. PubMed ID: 36716293
[TBL] [Abstract][Full Text] [Related]
10. Effects of different applied voltages of irreversible electroporation on prostate cancer in a mouse model.
Kim HB; Zeng CH; Kim Y; Jeong S; Kim SH; Kang JM; Park Y; Won DS; Kim JW; Ryu DS; Lim B; Park JH
Sci Rep; 2022 Dec; 12(1):22336. PubMed ID: 36572706
[TBL] [Abstract][Full Text] [Related]
11. Down-Regulation of Neogenin Decreases Proliferation and Differentiation of Spermatogonia during the Early Phase of Spermatogenesis.
Park JW; Kim YJ; Lee SJ; Ko JJ; Kim DK; Lee JH
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499089
[TBL] [Abstract][Full Text] [Related]
12. Exploring the Characteristics of Circulating Tumor DNA in Pt1a Clear Cell Renal Cell Carcinoma: A Pilot Study.
Kim H; Park JS; Choi Z; Min S; Park J; Shin S; Choi JR; Lee ST; Ham WS
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444416
[TBL] [Abstract][Full Text] [Related]
13. Pyruvate dehydrogenase kinase regulates vascular inflammation in atherosclerosis and increases cardiovascular risk.
Forteza MJ; Berg M; Edsfeldt A; Sun J; Baumgartner R; Kareinen I; Casagrande FB; Hedin U; Zhang S; Vuckovic I; Dzeja PP; Polyzos KA; Gisterå A; Trauelsen M; Schwartz TW; Dib L; Herrmann J; Monaco C; Matic L; Gonçalves I; Ketelhuth DFJ
Cardiovasc Res; 2023 Jul; 119(7):1524-1536. PubMed ID: 36866436
[TBL] [Abstract][Full Text] [Related]
14. Grave-to-cradle: human embryonic lineage tracing from the postmortem body.
Choi SH; Ku EJ; Choi YA; Oh JW
Exp Mol Med; 2023 Jan; 55(1):13-21. PubMed ID: 36599930
[TBL] [Abstract][Full Text] [Related]
15. Abrogating PDK4 activates autophagy-dependent ferroptosis in breast cancer via ASK1/JNK pathway.
Shi W; Wang J; Chen J; Jin X; Wang Y; Yang L
J Cancer Res Clin Oncol; 2024 Apr; 150(4):218. PubMed ID: 38678126
[TBL] [Abstract][Full Text] [Related]
16. USP5 facilitates bladder cancer progression by stabilizing the c-Jun protein.
Zhang HH; Zhang AQ; Peng P; Huang L; Liu CY; Nie XR; Hou DF; Zhang X; Li SZ
Cancer Cell Int; 2024 Jan; 24(1):32. PubMed ID: 38229092
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapies in bladder cancer: signaling pathways, applications, and challenges.
Peng M; Chu X; Peng Y; Li D; Zhang Z; Wang W; Zhou X; Xiao D; Yang X
MedComm (2020); 2023 Dec; 4(6):e455. PubMed ID: 38107059
[TBL] [Abstract][Full Text] [Related]
18. Pyruvate Dehydrogenase Kinase 4 Deficiency Increases Tumorigenesis in a Murine Model of Bladder Cancer.
Woolbright BL; Rajendran G; Abbott E; Martin A; Didde R; Dennis K; Harris RA; Taylor JA
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980540
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
